Intrauterine Infection and Mother-to-Child Transmission of Hepatitis B Virus: Route and Molecular Mechanism

Xianlei Zhao¹,², Xiaoxia Bai¹, Yongmei Xi¹,²

¹Division of Human Reproduction and Developmental Genetics, the Women’s Hospital, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310006, People’s Republic of China; ²Institute of Genetics and Department of Human Genetics, Zhejiang Provincial Key Laboratory of Genetic & Developmental Disorders, Zhejiang University School of Medicine, Hangzhou City, Zhejiang Province, 310058, People’s Republic of China

Correspondence: Yongmei Xi, Email xyyongm@zju.edu.cn

Abstract: In high prevalence settings, mother-to-child transmission is responsible for more than 50% of chronic Hepatitis B Virus (HBV) infections with 1–9% of newborns of HBV-carrying mothers acquiring HBV in early life. Little is known about the routes and cellular mechanisms by which HBV intrauterine transmission occurs. Clinical studies indicate that placental trophoblasts can be infected with HBV. In vitro studies using primary trophoblast and cell lines support this hypothesis. Several cellular parameters, including the differentiation state of the trophoblasts, cytokine secretion, and the surface molecules involved in virus entry, may influence the receptivity of trophoblastic cells to HBV. In HBV-infected trophoblastic cells, a reduction of apoptosis and increased production of antiviral cytokines has been observed, presumably via an HBx antigen-Akt or TLRs-MyD88-NF-κB pathway. Trophoblast HBV infection occurrence involves complex pathological processes with little currently known of the related mechanisms within infected cells. Whilst much focus has been on the placental routes of infection, through trophoblasts in particular, other routes have also been suggested. In this article, we review the models for HBV mother-to-child transmission and discuss the possible mechanisms of HBV intrauterine transmission with particular emphasis upon the involvement of placental trophoblast infection.

Keywords: hepatitis B virus, intrauterine infection, trophoblastic cell, mother-to-child transmission

Introduction

Chronic hepatitis B virus infection remains a serious global health issue affecting approximately 240 million people worldwide.¹ In high prevalence/endemic areas, HBV transmission is usually either horizontally, through shared needles or contaminated blood transfusion; or vertically, where mother-to-child transmission accounts for more than 50% of chronic HBV infections.²,³ More than 80% of those infected perinatally or during early childhood will become chronic viral carriers, leading to significantly increased risk of diseases associated with liver injury in later adulthood.⁴ Mother-to-child transmission of HBV can occur prenatally during pregnancy, nataly during labor, or postnatally through close contact such as in breastfeeding. Most vertical transmissions occurring perinatally are to newborns without prior HBV vaccination. However, numerous reports have shown that, despite timely immunoprophylaxis with vaccines and HB immunoglobulin (HBIG), 1–9% of newborns of mothers with HBeAg and/or HBV DNA seropositivity still go on to acquire HBV in early childhood.⁵,⁶

Prevention of transmission during pregnancy presents a difficult challenge as little is known about the routes or intracellular mechanisms utilized by HBV in its transport from mother to fetus. Intrauterine infection can also occur at different times and stages during gestation ranging from gamete infection,⁷–⁹ to occurrence associated with the transport of contaminated maternal blood and peripheral blood mononuclear cells (PBMCs) occurring as early as second trimester¹⁰,¹¹ or via the placenta. In these, accumulating evidence¹²–¹⁵ seems to implicate the primacy of HBV transplacental infection and propose diverse models of intrauterine infection. The overall objective of this study is to
summarize the current evidence supporting the primacy of HBV transplacental transmission with an emphasis on trophoblast infection given its strategic value in the placental barrier.

**Epidemiology**

Though a 20-year effort in childhood vaccination in China has resulted in a 97% reduction of HBV infections, China still retains the largest pool of HBV infection in Asia with a prevalence of more than 80 million estimated chronic infections in 2018.\(^1\) The application of HBV vaccines in combination with HBIG has greatly reduced the incidence of perinatal HBV transmission. The prevalence of HBsAg in the Chinese 1–29 age group has dropped dramatically from 10.13% in 1997 to 2.64% in 2014.\(^16\) Nevertheless, these strategies do not completely block the mother-to-child transmission of HBV\(^17\)–\(^19\) and immunoprophylaxis failure occurs in 1–9% of newborns,\(^5,6\) in which case infants born to HBV-carriers still suffer HBV infection. Conversely, the likelihood for adults to become chronic carriers upon exposure is much lower, being from 5% to 10%.\(^3,20\) In other words, infants and children are more prone to chronic HBV infections than adults. This sharp contrast highlights the strong requirement to place our primary focus for this disease on the prevention of mother to child transmission during pregnancy and delivery.

**Criteria for Mother-to-Child Transmission of HBV**

The transmission from the infected mother to the offspring is traditionally termed as mother-to-child transmission (MTCT), including transmission before birth, during birth and in early childhood. In this article, we mainly focus on transmission during pregnancy, which is referred to as intrauterine transmission. The definition of HBV intrauterine transmission is still controversial with various sources offering differing diagnostic criteria including: 1) Serum HBsAg and/or HBeAg positivity or HBV DNA positivity after birth;\(^11,21,22\) 2) Serum HBsAg and/or HBeAg positivity or HBV DNA positivity after birth, lasting >2 months;\(^18,23\) 3) Persistent serum anti-HBe IgM-positive after birth.\(^24\) The lack of consistency in such criteria inevitably leads to varying rates of mother-to-child transmission, depending on which definition is used. The surprisingly high rate of MTCT in some studies can be attributed to the fact that the authors had only tested from neonate HBV seromarkers at birth, with no follow-up visit. In such cases, HBsAg and HBV DNA seropositivity in the infant directly after birth could be a result of transient antigenemia and could disappear with 8–12 months. Such serological indexes could also be removed via host immunity and/or vaccination.\(^25,26\) Such positive markers that are no longer detectable during follow-up visits are often considered as the positive result having been transferred from the infected mother, rather than showing an established HBV infection in the infant.\(^25,26\) However, a small proportion of new-borns still exhibited seropositivity during follow-ups, unprevented by HBV immunoprophylaxis, representing true cases of transmission during pregnancy.

**Models of HBV Vertical Intrauterine Transmission**

The vertical transmissions of HBV occur mainly during delivery or by intrauterine transmission. Several models of intrauterine transmission of HBV have been proposed. These include infection via paracellular routes (transplacental leakage and PBMCs), germline infection, and placental infection.

**Transplacental Leakage**

Transplacental leakage has been viewed as the most common route for intrauterine transmission when preterm labor is threatened or where abortion causes uterine muscle contraction, consequently leading to rupture of the placental barrier and allowing direct exchange between maternal blood and fetal blood.\(^5\) Transplacental leakage can also occur during early pregnancy due to placental immaturity, or during invasive procedures such as chorionic sampling and amniocentesis. In such cases, the mix of fetal peripheral blood with maternal blood, as a consequence of partial breakdown in placental barrier, introduces HBV-containing blood into fetal circulation causing in utero infant HBV infection. A number of studies have been published regarding this route of transmission. However, conflicting results have been presented where Ohto et al\(^27\) and Lin et al\(^28\) suggested that HBV intrauterine transmission is associated with a history of preterm labor or preterm abortion, whereas Tang et al\(^29\) indicated otherwise. This discrepancy may be due to the small sample sizes represented by these three papers. A fuller case-control study of 402 newborns recruited from 402 HBsAg positive
mothers showed that maternal HBeAg seropositivity (OR = 14.46 and 17.07 from univariate and multivariate analysis, respectively) and threatened preterm labor (OR = 6.66 and 5.44) were significantly associated with HBV intrauterine transmission and identified as major risk factors. This was further verified by a recent study conducted among 96 HBsAg positive women and their infants. Notably, many studies, including those covering cases of c-section, showed that even where there was no evidence of transplacental leakage, HBeAg was still able to cross the placenta and induce infant T-cell tolerance for HBV in the infant.

**PBMCs**

HBV may not be strictly hepatotropic. Studies have confirmed its presence in PBMCs. As an extrahepatic reservoir for HBV, PBMCs have been closely associated with HBV chronic infection or HBV reoccurrence with various forms of HBV DNA detected within PBMCs. The significant association between HBV intrauterine transmission and HBV DNA in PBMCs suggests that HBV-infected PBMCs may serve as a vector for HBV transfer from mother to fetus. Xu et al conducted a population-based nested case-control study with 312 HBsAg seropositive mothers and their 312 newborns. Among these, 26% of neonates were detected with HBV DNA in PBMCs and a 67% rate of infant infection was noted from mothers with HBV DNA in PBMCs. Infants born to HBV DNA-seronegative but HBV DNA-positive PBMCs mothers were at a 5 times higher risk of HBV infection than those born to mothers with HBV DNA negativity in PBMCs. This indicates that HBV-infected PBMCs contribute to intrauterine transmission. However, any further conclusions relating to the significance of PBMC infection remain limited by the lack of follow-up studies for such HBV-infected infants.

**Germline Infection**

The germline infection model depicts HBV infection at the time of conception via either oocyte or sperm where HBV has been shown to invade and replicate within ova. The presence and expression of HBV within the oocyte is closely associated with the HBV DNA level and infection status of the mother. Additional information is required for this phenomenon due to conflicting results as to whether infected oocytes can transmit the virus vertically to the offspring. In addition to blood and liver, HBV can also be detected in semen. Evidences that HBV can integrate its DNA into the male spermatozoa genome have been presented. It remains controversial as to whether HBV DNA sequences can be passed onto the embryos through infected spermatozoa. In spite of various studies using animal models supporting this theory, it is unclear whether this occurs in humans, with conflicting results from a number of studies.

**Placental Infection**

The placenta is a highly specialized organ that not only generates a nourishing environment for fetal development, but also acts as a barrier against the transmission of blood-borne pathogens. The placental barrier is composed of four elements. From the fetal to the maternal side these are the fetal endothelial cells, the connective tissues that surround the fetal capillaries, the cytotrophoblasts and the syncytiotrophoblasts. Pathogens within maternal blood need to cross those layers of cells in order to reach fetal circulation and consequently infect the fetus.

Various studies have confirmed the presence of HBV, including HBsAg and HBV DNA, in each of these layers of placental tissue. A study by Bai et al examined such placental tissues for HBV infection by RT-PCR and immunohistochemistry. The seromarker HBsAg was present in 5 cases out of 6 infants with positive cord blood, and HBV DNA was noted in the placental tissues, although at a relatively low level of $5.0 \times 10^2$–$3.0 \times 10^3$ copy/mL. In 20 women whose serum tested positive for HBV DNA, 6 cases showed positive immunohistochemical staining of HBsAg in their placental tissues, 5 of which exhibited positive staining of villous trophoblasts and mesenchymal cells, and with one case of positive staining of villous capillary endothelial cells. Xu et al found that the rate of HBV infection in different cell layers of placental tissues gradually decreased from the maternal side to fetal side, with the highest positivity rate of HBsAg, HBcAg, and HBV DNA in decidual cells, followed by trophoblasts, villous mesenchymal cells and villous capillary endothelial cells. These results were consistent with those from a research study by Chen et al, which confirmed that the rate of HBV infection differed among the cell layers of placental tissues. A recent study also unveiled the positive correlation between HBV intrauterine transmission and placental cell infection, with OR 4.6 (95% CI 2.29–
These articles concluded that the closer to the fetus the HBV infection occurred, the higher the risk of HBV intrauterine transmission.

An added complication is that the composition of the placental barrier changes as pregnancy progresses. In early pregnancy, cytotrophoblasts predominate within the placental villi, whereas late in gestation mononucleated cytotrophoblasts differentiate and fuse into a continuous layer of syncytiotrophoblasts, forming the primary barrier between the maternal and fetal circulation. One in vitro study has suggested that the formation of this continuous barrier is associated with the reduction of the potential to transmit a virus. Evidence for this was presented in that the monolayer of differentiated BeWo cells did not transcytose HBV as effectively as forskolin-untreated cells where the former exhibited a reduction rate of 24%. However, a contrasting clinical study by Chang et al challenged this, where in 25 examined cases of first-trimester villi tissues from HBsAg-seropositive women, 8 cases were detected with positive HBV signals. This inconsistency may result from the small sample size and the somewhat descriptive nature of these two clinical studies.

Despite the conflicting results pertaining to the role of placenta differentiation status on its susceptibility to HBV, different gestation stages at the time of infection with different infection outcomes have been reported for other viruses, such as HIV, B19, and CMV. For example, it has been proposed that cytotrophoblasts isolated from first-trimester villi are susceptible to HIV-1, while syncytiotrophoblasts from third-trimester villi develop potent infections. Maternal exposure to B19 at the second-trimester stage has also been associated with a higher risk of vertical transmission. Furthermore, early and mid-gestation trophoblasts are noted as prone to CMV infection, whereas late term trophoblasts cannot be infected with CMV. In addition to in vivo evidence for the presence of HBV within placental trophoblasts, there are also numerous in vitro studies investigating the infection mechanism of trophoblasts with HBV, which will be discussed in the next section.

**Molecular Mechanism of Trophoblast Infection with HBV**

**Transcytosis of HBV in Trophoblastic Cell Lines**

An in vitro system using the human trophoblast-derived BeWo cell line, a choriocarcinoma cell line grown as polarized monolayers on semipermeable membranes, showed that BeWo was able to transcytose infectious HBV particles in an endosome-dependent manner. Our recent study demonstrated the transcytosis of HBV across trophoblasts using trophoblastic cell line Swan71 and primary trophoblasts. BeWo cells could actively transcytose HBIG and the reduced virus transcytosis rate was thought to be due to the formation of HBV-IgG complexes which were internalized via the Fc receptor. Additionally, HBV transcytosis efficiency was reduced with the fusion of cytotrophoblasts into syncytiotrophoblasts and with the addition of HBIG. As previously mentioned, HBV transcytosis was noted as inhibited by mononucleated trophoblast differentiation into multinucleated syncytiotrophoblasts, and infection efficiency and outcomes are seen to vary with gestation stages. This may be attributed to the different protein expression profiles of the different stages of the trophoblasts. In human liver cells and other hepatic cell lines, HBV’s specific binding to the cell surface is known to be mediated by the hepatotropic receptor NTCP, a process in which many other surface molecules also contribute as co-receptors, such as FTL, SCCA-1, and HSPGs. However, HBV infections are not restricted to hepatocytes. As far as receptors on trophoblasts are concerned, the Fc receptor family has been studied extensively and its distribution across the placenta is well understood.

**Fc Receptor-Mediated HBsAg-Anti-HBs Uptake into Trophoblasts**

Consistent with previous findings, the Fc receptor III was found to be expressed on placental trophoblasts and villous mesenchymal cells, whereas the Fc receptor II was found solely on villous mesenchymal cells. In the placenta, trophoblasts are particularly known to transfer IgG from maternal circulation to the fetus, through Fc receptor-mediated entry of immune complexes of infectious origins. The presence of maternal HBIG has been correlated with a lower level of HBV intrauterine transmission. This is supported by a meta-analysis of research data derived from 37 individual studies. In addition, postnatal HBIG injection of the infants was effective and prevented HBV horizontal transmission after birth. Bhat & Anderson discovered that beyond the addition of anti-HBV IgG at 100mg/L, HBV transcytosis
decreased by a modest but significant degree. It was supposed that this was due to the formation of complexes between HBV anti-HBV IgG.

However, Xu et al\textsuperscript{13} in their immunohistochemistry study examined 2 placental tissues from 2 HBV-seropositive women for detection of HBsAg and anti-HBs. They observed the presence of HBsAg-anti-HBs complex in the cytoplasm and on the surface of trophoblastic cells and in the mesenchymal cells of both areas. Thus, the presence of maternal IgG in the placenta against HBV may be double-edged in that IgG coupled with HBV may be internalized into the trophoblasts through Fc \( \gamma \) receptor-mediated entry.\textsuperscript{56} Further studies are required to elucidate whether transcytosed HBV occurs in a free form or to investigate the infectivity of transcytosed HBV particles.

**Toll-Like Receptors-Mediated HBV Infection in Trophoblasts**

Toll-like receptors are a family of molecules that recognize pathogen-associated molecular patterns (PAMP) and activate downstream antiviral pathways. In addition to surface molecules that facilitate HBV transmission across trophoblasts, the expression of Toll-like receptors (TLR) in trophoblasts has been reported to be involved in preventing intrauterine transmission\textsuperscript{57} where the placental expression level of TLR7 is significantly higher in cases of intrauterine transmission. In Swan\textsuperscript{71}, an immortalized trophoblastic cell line, exposure to HBV greatly induced the expression of TLR7, TLR8, MyD88, and some intracellular antiviral cytokines, such as interferon-\( \alpha \) (IFN-\( \alpha \)), IFN-\( \beta \), and interleukin-8 (IL-8).\textsuperscript{57} As a universal adaptor for TLRs in hepatic cells, knockdown of MyD88 in trophoblastic cells significantly increased the amount of transcytosed HBV.\textsuperscript{57} It was hypothesized that TLRs in trophoblasts are likely involved in the prevention of HBV intrauterine transmission via the recruitment of the effector protein MyD88, which then triggers the activation of NF-kappa B and subsequently generates an inflammatory response against HBV.

**Cytokines May Promote HBV Infection in Trophoblasts**

The placenta is a complex environment where a variety of soluble cytokines play key roles in gestation and are necessary for successful pregnancy. These include IL-1,3,4,6, transforming growth factor-\( \beta \) (TGF-\( \beta \)), IFN-\( \gamma \), and tumor necrosis factor-\( \alpha \) (TNF-\( \alpha \)). Some cytokines in the placental microenvironment may also play a regulatory role in protecting the fetus or conversely, in driving viral expression.\textsuperscript{58} In support of this theory, two studies have provided evidence of enhanced HBV uptake into choriocarcinoma cell lines such as JAR, JEGIII and primary trophoblasts in the presence of TNF-\( \alpha \).\textsuperscript{58,59} The susceptibility to HBV of JAR cells was significantly enhanced in the presence of the cytokine TNF-\( \alpha \).\textsuperscript{58} Similar results showed that in vitro infection with HBV induces the accumulation of HBV DNA and HBsAg and leads to an increase in the secretion of HBsAg within JEGIII, all of which were significantly enhanced by the addition of TNF-\( \alpha \).\textsuperscript{59}

**Suppressed Apoptosis in HBV-Infected Trophoblasts via Smad and PI3K/pAKT Signaling**

HBV was first reported to be involved in the reduction of apoptosis in trophoblasts via the stimulation of PI3K/pAKT signaling.\textsuperscript{60} Using the choriocarcinoma cell line JEGIII as a model for in vitro infection, they successfully detected intracellular HBV DNA with expressions of HBx mRNA and HBxAg exhibiting decreases in their proportions in cells at both early and late apoptosis, and with corresponding increases in the levels of PI3K and PAKT.\textsuperscript{60} Overexpression of the HBx protein in the trophoblastic cell line HTR-8/SVneo inhibited apoptosis and increased the invasive ability of HBx-transfected cells. An increased mRNA level of inflammatory factors IL-6 and IL-10 was also detected with Western blot indicating higher levels of pSmad2 and pSmad3 in the transfected cells.\textsuperscript{61} This increased inflammatory response and invasion activity may have resulted from the activation of the Smad signaling pathway. Therefore, the inhibition of apoptosis induced by HBx may prolong the survival of HBV-infected trophoblasts and thus provide an opportunity for a latent infection and the subsequent infection of surrounding cells (Figure 1). This coincides with the results of Bai et al,\textsuperscript{62} showing a higher clinical expression of HBxAg and PI3K, and a decrease in the apoptotic index in placental tissues from women of the high replication group (serum HBV DNA \( \geq 1 \times 10^3 \) copies/mL), in comparison with those of the low replication group (serum HBV DNA \( <1 \times 10^3 \) copies/mL). In a more recent study,\textsuperscript{63} a constructed plasmid to express
HBx was transfected into JEGIII cells where similar results were achieved. This supported the understanding that HBV induces a reduction in apoptosis via HBxAg.

**HBx Reduces Apoptosis in Trophoblasts via EGFR/Akt Signaling Pathways**

The intracellular EGFR/Akt signaling pathway has been recently identified to be involved in trophoblastic infection with HBV. A lower degree of apoptosis was observed in HBx-expressing JEGIII cells, while a higher level of pEGFR was detected both in placental tissues from HBV carriers and in HBx-transfected JEGIII cells. Both the upregulation of pAkt and reduced apoptosis could be offset by the EGFR inhibitor gefitinib. In addition, the knockdown of HBx suppressed the activation of the EGFR/Akt pathway and increased cellular apoptosis, whereas EGF stimulation counteracted this effect. This supports the hypothesis that HBx reduces apoptosis in trophoblasts, possibly through the activation of the EGFR/Akt signaling pathway. This suggested that HBx inhibits trophoblast cell apoptosis by activating the EGFR/Akt signaling pathway. In addition, a recent study demonstrates that HBx promotes HBV replication in trophoblasts via downregulation of Smc5/6, activates the EGFR promoter and inhibits trophoblast apoptosis via the PI3K/p-AKT downstream signaling pathway. Therefore, the anti-apoptotic pathways induced by HBx might contribute to the intrauterine transmission of HBV (Figure 1).

**Conclusion**

Mother-to-child transmission (MTCT) is the major cause of chronic infection of hepatitis B virus (HBV) in patients. Clarification of the routes and cellular mechanisms by which HBV intrauterine transmission occurs is of high importance. Clinical studies have verified that placental cells, trophoblasts in particular, can be infected with HBV. A number of in vitro studies using isolated primary trophoblasts and trophoblastic cell lines have suggested that trophoblast infection with HBV depends on trophoblastic surface receptors such as Fcγ and TLRs and is correlated with reduced apoptosis via various pathways. We have recently proposed as an unconventional protein secretion pathway, autophagy may be hijacked by HBV to complete the process of intracellular transport and exocytosis. In the HBV infected trophoblasts, AnxA2–S100A10 complex-mediated exocytosis could result in HBV intrauterine transmission. However, exactly how HBV enters trophoblasts, the intracellular transport mechanism of the virus, and how HBV egresses out of trophoblasts
still awaits clarification. In this way more effort is required to clarify the intracellular events responsible for trophoblast infection with HBV.

Acknowledgments
This work was funded by the Fundamental Research Funds for the Central Universities (17221012101) and National Natural Science Foundation of China (81671478). We thank Chris Wood for English language support.

Author Contributions
X.Z and Y.X. took part in drafting, revising or critically reviewing the article. Y.X. and X.B gave final approval of the version to be published. All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.

Disclosure
The authors report no conflicts of interest.

References
Zhao et al


